TRAVERE THERAPEUTICS, INC. Increase (Decrease) in Income Taxes Receivable
TRAVERE THERAPEUTICS, INC. (TVTX) reported Increase (Decrease) in Income Taxes Receivable of -$849.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2022-12-31 was -$22.00K.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2022-09-30 was $264.00K, a 5180.00% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2021-12-31 was -$93.00K, a 102.64% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2021-09-30 was $5.00K.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2025 was -$849.00K, a 2170.73% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2024 was $41.00K, a 17.14% increase from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2023 was $35.00K, a 90.64% decline from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2022 was $374.00K.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$849.00K 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $41.00K 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $35.00K 10-K · filed 2026-02-19 | |||
| 2022-12-31 | -$22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $242.00K derived: sum of 2 quarters · filed 2025-02-21 | $374.00K 10-K · filed 2025-02-21 | |
| 2022-09-30 | $264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $396.00K 10-Q · filed 2022-10-27 | ||
| 2022-06-30 | $132.00K 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$88.00K derived: sum of 2 quarters · filed 2024-02-20 | -$16.86M derived: sum of 3 quarters · filed 2024-02-20 | -$17.10M 10-K · filed 2024-02-20 |
| 2021-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$16.77M derived: sum of 2 quarters · filed 2022-10-27 | -$17.01M 10-Q · filed 2022-10-27 | -$13.48M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$16.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$17.01M 10-Q · filed 2022-08-04 | -$13.48M derived: sum of 3 quarters · filed 2023-02-23 | -$19.98M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$238.00K 10-Q · filed 2021-05-06 | $3.29M derived: sum of 2 quarters · filed 2023-02-23 | -$3.21M derived: sum of 3 quarters · filed 2023-02-23 | -$3.28M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$2.97M derived: sum of 2 quarters · filed 2023-02-23 | -$3.04M derived: sum of 3 quarters · filed 2023-02-23 | $15.75M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$6.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | -$6.57M derived: sum of 2 quarters · filed 2021-10-29 | $12.22M 10-Q · filed 2021-10-29 | $11.66M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $18.71M 10-Q · filed 2021-07-29 | $18.16M derived: sum of 3 quarters · filed 2022-02-24 | $18.16M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $18.79M 10-Q · filed 2021-05-06 | $18.23M derived: sum of 2 quarters · filed 2022-02-24 | $18.23M derived: sum of 3 quarters · filed 2022-02-24 | $18.54M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$555.00K derived: sum of 2 quarters · filed 2022-02-24 | -$251.00K derived: sum of 3 quarters · filed 2022-02-24 | -$555.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $304.00K derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $304.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | -$304.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$1.13M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |